Article Sidebar
Published:
Mar 16, 2016Article Details
Copyright remains in the Author’s name. The work is licensed under a Creative Commons Attribution - Noncommercial Works License. Authors are required to complete and sign an Author Agreement form that outlines Author and Publisher rights and terms of publication. The Agreement form should be uploaded along with other submissions files and any submission will be considered incomplete without it [forthcoming].
Material submitted for publication in the SAMJ is accepted provided it has not been published or submitted for publication elsewhere. Please inform the editorial team if the main findings of your paper have been presented at a conference and published in abstract form, to avoid copyright infringement. The SAMJ does not hold itself responsible for statements made by the authors.
Previously published images
If an image/figure has been previously published, permission to reproduce or alter it must be obtained by the authors from the original publisher and the figure legend must give full credit to the original source. This credit should be accompanied by a letter indicating that permission to reproduce the image has been granted to the author/s. This letter should be uploaded as a supplementary file during submission.
Main Article Content
An investigation of the occurrence of sv40 antibodies in South Africa
Abstract
We developed an enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies to simian virus 40 (SV40) in human serum. We then used the ELISA to test for anti-SV40 antibodies in healthy inviduals and patients suffering from cancer and renal diseases. The aim of the study was to determine the presence of antibodies against SV40 in sera of individuals who received the South African poliovirus vaccines from 1958 to the present. Detecting such antibodies could give an indication of whether any of the poliovirus vaccines used in South Africa were ever contaminated with the SV40 or not. A total of 5/164 samples were repeatedly positive for SV40 antibodies by the ELISA. Four of the samples were from the healthy population group and the remaining 1 (1/64) was from the patient group. An SV40 antibody-blocking assay and a Western blot were used as additional confirmation for the SV40 antibodies, whereas the Western blot assay developed a single common band on all 5 samples.
